Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University, Baltimore, Maryland.
HCor Neuroscience Institute, Heart Hospital (HCor), São Paulo, São Paulo, Brazil.
Int J Radiat Oncol Biol Phys. 2021 Sep 1;111(1):68-80. doi: 10.1016/j.ijrobp.2021.04.016. Epub 2021 Apr 20.
The purpose of this critical review is to summarize the literature specific to single-fraction stereotactic radiosurgery (SRS) and multiple-fraction stereotactic radiation therapy (SRT) for postoperative brain metastases resection cavities and to present practice recommendations on behalf of the ISRS.
The Medline and Embase databases were used to apply the Preferred Reporting Items for Systematic Reviews and Meta-Analyses approach to search for manuscripts reporting SRS/SRT outcomes for postoperative brain metastases tumor bed resection cavities with a search end date of July 20, 2018. Prospective studies, consensus guidelines, and retrospective series that included exclusively postoperative brain metastases and had at minimum 100 patients were considered eligible.
The Embase search revealed 157 manuscripts, of which 77 were selected for full-text screening. PubMed yielded 55 manuscripts, of which 23 were selected for full text screening. We deemed 8 retrospective series, 1 phase 2 prospective study, 3 randomized controlled trials, and 1 consensus contouring paper appropriate for inclusion. The data suggest that SRS/SRT to surgical cavities with prescription doses of 30 to 50 Gy equivalent effective dose (EQD) 2, 50 to 70 Gy EQD2, and 70 to 90 EQD2 are associated with rates of local control ranging from 60.5% to 91% (median, 80.5%). Randomized data suggest improved local control with single-fraction SRS compared with observation and improved cognitive outcomes compared with whole-brain radiation therapy (WBRT). The toxicity of SRS/SRT in the postoperative setting was limited and is reviewed herein.
Although randomized data raise concern for poorer local control after resection cavity SRS than WBRT, these findings may be driven by factors such as conservative prescription doses used in the SRS arm. Retrospective studies suggest high rates of local control after single-fraction SRS and hypofractionated SRT for postoperative brain metastases. With a superior neurocognitive profile and no survival disadvantage to withholding WBRT, the ISRS recommends SRS as first-line treatment for eligible postoperative patients. Emerging data suggest that fractionated SRT may provide superior local control compared with single-fraction SRS, in particular, for large tumor cavity volumes/diameters and potentially for patients with a preoperative diameter greater than 2.5 cm.
本综述的目的是总结单次立体定向放射外科(SRS)和多次立体定向放射治疗(SRT)在术后脑转移瘤切除术后的文献,并代表国际立体定向放射外科研究学会(ISRS)提出实践建议。
使用 Medline 和 Embase 数据库,采用系统评价和荟萃分析的首选报告项目方法,搜索截至 2018 年 7 月 20 日报告术后脑转移瘤肿瘤床切除术后 SRS/SRT 结果的文献。纳入标准为前瞻性研究、共识指南和仅包括术后脑转移瘤且至少有 100 例患者的回顾性系列研究。
Embase 搜索显示 157 篇手稿,其中 77 篇被选为全文筛选。PubMed 产生了 55 篇手稿,其中 23 篇被选为全文筛选。我们认为 8 项回顾性系列研究、1 项 2 期前瞻性研究、3 项随机对照试验和 1 项共识轮廓论文适合纳入。数据表明,处方剂量为 30 至 50 Gy 等效有效剂量(EQD)2、50 至 70 Gy EQD2 和 70 至 90 EQD2 的 SRS/SRT 治疗手术腔与 60.5%至 91%(中位数 80.5%)的局部控制率相关。随机数据表明,与观察相比,单次 SRS 治疗比单次 SRS 治疗更能提高局部控制率,与全脑放疗(WBRT)相比,认知功能改善。术后 SRS/SRT 的毒性是有限的,本文对此进行了综述。
尽管随机数据表明,与 WBRT 相比,术后切除腔 SRS 后的局部控制率较差,但这些发现可能是由于 SRS 臂中使用的保守处方剂量等因素所致。回顾性研究表明,单次 SRS 和术后脑转移分次 SRT 治疗的局部控制率较高。由于具有优越的神经认知特征且不拒绝 WBRT 治疗不会带来生存劣势,ISRS 建议 SRS 作为有资格的术后患者的一线治疗方法。新出现的数据表明,与单次 SRS 相比,分次 SRT 可能提供更好的局部控制,特别是对于较大的肿瘤腔体积/直径和术前直径大于 2.5cm 的患者。